LEAC 102Alternative Names: LEAC-102
Latest Information Update: 26 Jul 2016
At a glance
- Originator Taiwan Biotech Co Ltd
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 21 Jul 2016 Preclinical trials in Gastrointestinal cancer in Taiwan (PO)
- 21 Jul 2016 Taiwan Leader Biotech plans a phase I/IIa trial for Gastrointestinal cancer in Taiwan and US (NCT02826837)